<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01548677</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-90091-10093</org_study_id>
    <secondary_id>2009-017485-23</secondary_id>
    <nct_id>NCT01548677</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer</brief_title>
  <acronym>TREAT-CTC</acronym>
  <official_title>TRastuzumab in HER2-negative Early Breast Cancer as Adjuvant Treatment for Circulating Tumor Cells (CTC) (&quot;TREAT CTC&quot; Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen Diagnostics, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>SUCCESS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized phase II trial for patients with HER2 negative primary Breast Cancer&#xD;
      (BC) who after completing (neo) adjuvant chemotherapy and surgery have detectable circulating&#xD;
      tumour cells (CTC) in peripheral blood.&#xD;
&#xD;
      Eligible patients will be randomised in 1:1 ratio to either the trastuzumab arm or the&#xD;
      observation arm.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized phase II trial for patients with HER2 negative primary BC who after&#xD;
      completing (neo) adjuvant chemotherapy and surgery have detectable CTC(s) in peripheral blood&#xD;
      (see eligibility criteria for details). Eligible patients will be randomized in 1:1 ratio to&#xD;
      either the trastuzumab arm or the observation arm. Patients randomized to the trastuzumab arm&#xD;
      will receive a total of 6 intravenous (IV) administrations every 3 weeks (loading dose 8&#xD;
      mg/kg IV and 5 cycles at 6 mg/kg every 3 weeks). Patients randomized to observation arm shall&#xD;
      be observed for 18 weeks. Left ventricular ejection fraction (LVEF) assessment (MUGA and/or&#xD;
      ECHO) will be done at baseline for all patients to be randomized. The next LVEF assessments&#xD;
      of weeks 9 and week 18 will be done only in patients randomized to trastuzumab arm. Patient&#xD;
      registered but with CTC negative result will not be followed-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CTC detection</measure>
    <time_frame>18 weeks post randomisation</time_frame>
    <description>To compare circulating tumour cell (CTC)detection rate at week 18 between trastuzumab treatment arm and observational arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>RFI (recurrence free interval)</measure>
    <time_frame>2 years after LPI (last patient in)</time_frame>
    <description>Recurrence Free Interval (RFI) (key secondary endpoint) between trastuzumab and observation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IDFS (Invasive Disease Free Survival)</measure>
    <time_frame>2 years after LPI</time_frame>
    <description>Invasive Disease Free Survival between trastuzumab and observation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DFS (disease free survival)</measure>
    <time_frame>2 years after LPI</time_frame>
    <description>Disease Free survival between trastuzumab and observation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS (overall survival)</measure>
    <time_frame>2 years after LPI</time_frame>
    <description>Overall Survival between trastuzumab and observation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CTC essay</measure>
    <time_frame>2 years after LPI</time_frame>
    <description>To evaluate in a clinical trial setting the feasibility, reliability, within patient reproducibility and variability of the assay for CTC(s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CTC correlation</measure>
    <time_frame>2 years after LPI</time_frame>
    <description>To correlate CTC detection rate at baseline and/or week 18 with RFI, IDFS, DFS, OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety (cardiac)</measure>
    <time_frame>2 years after LPI</time_frame>
    <description>To assess safety, especially cardiac safety, of trastuzumab in women with HER2 negative primary tumors and CTC</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1317</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Human Epidermal Growth Factor 2 Negative Carcinoma of Breast</condition>
  <condition>Circulating Tumor Cells</condition>
  <arm_group>
    <arm_group_label>observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>18 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Herceptin (trastuzumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>18 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
    <description>8 mg/kg of loading dose IV over 90 minutes for the first cycle, followed by 6 mg/kg IV over 60 minutes every 3 weeks for the 5 subsequent cycles.</description>
    <arm_group_label>Herceptin (trastuzumab)</arm_group_label>
    <other_name>endocrine therapy</other_name>
    <other_name>anti HER2 therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Age ≥ 18 years&#xD;
&#xD;
          -  Written informed consent must be given according to ICH/GCP, and national/local&#xD;
             regulations&#xD;
&#xD;
          -  Availability of peripheral blood draw for CTC blood test&#xD;
&#xD;
          -  Tumor block or minimum 10 unstained slides of 4 μm of primary tumor must be available&#xD;
             prior to registration for centralized HER2 testing&#xD;
&#xD;
          -  ER status available&#xD;
&#xD;
          -  Adequately excised non-metastatic and non-relapsed operable primary invasive&#xD;
             HER2-negative adeno-carcinoma of the breast *:&#xD;
&#xD;
          -  the patient should have completed either&#xD;
&#xD;
          -  adjuvant chemotherapy or&#xD;
&#xD;
          -  neoadjuvant chemotherapy; in this case residual invasive disease in breast or lymph&#xD;
             nodes is required (no complete pathological response) no further adjuvant chemotherapy&#xD;
             treatment planned. Prior chemotherapy with doxorubicin restricted to a total dose of&#xD;
             360 mg/m2 or with epirubicin restricted to a total dose of 720 mg/m2 is allowed&#xD;
&#xD;
          -  No prior use of anti-HER2 therapy for any reason or immunotherapy for BC&#xD;
&#xD;
          -  No concomitant use of bisphosphonate therapy or denosumab for any reason. Prior use of&#xD;
             these agents is allowed provided that last treatment has been received at least 4&#xD;
             weeks before registration in the study&#xD;
&#xD;
          -  No prior mediastinal irradiation except internal mammary node irradiation for the&#xD;
             present BC&#xD;
&#xD;
          -  Concomitant adjuvant hormonal therapy or radiotherapy (if applicable) is allowed upon&#xD;
             physician's choice&#xD;
&#xD;
          -  The interval between definitive surgery (neoadjuvant population) or end of adjuvant&#xD;
             chemotherapy (adjuvant population) and registration must be at least 3 weeks but no&#xD;
             more than 24 weeks&#xD;
&#xD;
          -  No evidence of unresolved or unstable toxicity from prior surgery, adjuvant&#xD;
             chemotherapy or radiotherapy&#xD;
&#xD;
          -  No history of prior invasive breast carcinoma, except for the BC diagnosed and treated&#xD;
             before entry. Unifocal or multifocal unilateral (one breast) or unifocal or multifocal&#xD;
             synchronous bilateral breast (both breasts) cancer are acceptable if all invasive&#xD;
             tumor foci are HER2- negative. History of previous ductal carcinoma in situ is allowed&#xD;
&#xD;
          -  No history of any malignant neoplasms in the past 5 years except for curatively&#xD;
             treated basal and squamous cell carcinoma of the skin&#xD;
&#xD;
          -  No prior autologous or allogeneic stem cell transplantation&#xD;
&#xD;
          -  No history of serious cardiac illness or medical conditions, including but not&#xD;
             confined to:&#xD;
&#xD;
          -  History of documented congestive heart failure&#xD;
&#xD;
          -  High risk uncontrolled arrhythmias&#xD;
&#xD;
          -  Angina pectoris requiring anti-anginal medication&#xD;
&#xD;
          -  Clinically significant valvular heart disease&#xD;
&#xD;
          -  Evidence of transmural infarction on ECG&#xD;
&#xD;
          -  Poorly controlled hypertension (e.g. systolic &gt; 180 mm Hg or diastolic &gt; 100 mm Hg)&#xD;
&#xD;
          -  No history of other concurrent serious diseases that may interfere with planned&#xD;
             treatment, including severe pulmonary conditions&#xD;
&#xD;
          -  Absence of any psychological, familial, sociological or geographical condition&#xD;
             potentially hampering compliance with the study protocol and follow-up schedule; those&#xD;
             conditions should be discussed with the patient before registration&#xD;
&#xD;
          -  WHO performance status 0-1&#xD;
&#xD;
          -  No concurrent participation in another trial&#xD;
&#xD;
          -  No clinically significant active infections&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michail Ignatiadis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Jules Bordet, Brussels, Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martine Piccart, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Jules Bordet, Brussels, Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christos Sotiriou, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Jules Bordet, Brussels, Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Yves Pierga, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Curie, Paris, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brigitte Rack, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ludwig-Maximilians-Universitaet Muenchen - Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe - Innenstadt, Munich, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Onze Lieve Vrouw Ziekenhuis</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Universitaire Brugmann</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires Bordet-Erasme - Hopital Universitaire Erasme</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires Bordet-Erasme - Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital De Jolimont</name>
      <address>
        <city>Haine St Paul</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.Z. Leuven - Campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.U. Sart-Tilman</name>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique et Maternité Sainte Elisabeth</name>
      <address>
        <city>Namur</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Damiaan</name>
      <address>
        <city>Oostende</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Alpes Léman</name>
      <address>
        <city>Contamine sur Arve</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de la Dracénie</name>
      <address>
        <city>Draguignan</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble - La Tronche - Hôpital A. Michallon</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Departemental Vendée</name>
      <address>
        <city>La Roche Sur Yon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Versailles - Hopital Andre Mignot</name>
      <address>
        <city>Le Chesnay</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges - Hopital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique de la Sauvegarde</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier D'Annecy</name>
      <address>
        <city>Metz-Tessy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Mont-de-Marsan</name>
      <address>
        <city>Mont-de-Marsan</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Catherine De Sienne</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie - Hopital Rene Huguenin</name>
      <address>
        <city>Saint-Cloud</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires de Strasbourg - Hôpitaux Universitaires de Strasbourg - Hôpital civil</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux du Leman - Site Georges Pianta</name>
      <address>
        <city>Thonon les Bains</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Valence</name>
      <address>
        <city>Valence</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandoeuvre-Les-Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum St. Marien</name>
      <address>
        <city>Amberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Augsburg</name>
      <address>
        <city>Augsburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxisklinik Krebsheilkunde für Frauen</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Sindelfingen-Boeblingen</name>
      <address>
        <city>Boeblingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinischen Zentrum Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marienhospital Bottrop gGmbH</name>
      <address>
        <city>Bottrop</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Lorenz / Hecker / Wesche</name>
      <address>
        <city>Braunschweig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische-Hämatologischen Schwerpunktpraxis</name>
      <address>
        <city>Bremen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Gemeinschaftspraxis</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Luisenkrankenhaus GmbH &amp; Co. KG</name>
      <address>
        <city>Duesseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik Duesseldorf</name>
      <address>
        <city>Duesseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik Erlangen</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum - Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtische Kliniken</name>
      <address>
        <city>Esslingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ev.-Luth. Diakonissenanstalt Flensburg</name>
      <address>
        <city>Flensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtische Kliniken Frankfurt Am Main-Hoechst</name>
      <address>
        <city>Frankfurt Am Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaets-Krankenhaus Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gynäkologisch-Onkologischen Schwerpunktpraxis</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dr. Pourfard / Dr. Uleer</name>
      <address>
        <city>Hildesheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Marien-Klinik GmbH Frauenklinik der St. Vincentius-Kliniken gAG</name>
      <address>
        <city>Karlsruhe</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Schleswig-Holstein - Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Koeln</name>
      <address>
        <city>Koeln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Landshut</name>
      <address>
        <city>Landshut</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtisches Klinikum Leipzig - Klinikum St. Georg gGmbH</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Ludwigsburg</name>
      <address>
        <city>Ludwigsburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dr. Goldmann/ Dr. Ebert</name>
      <address>
        <city>Lueneburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitaetsMedizin Mannheim</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Prof. Salat / Dr. Stötzer</name>
      <address>
        <city>Muenchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ludwig-Maximilians-Universitaet Muenchen - Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe - Innenstadt</name>
      <address>
        <city>Muenchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Muencher Onkol. Praxis Elisenhof</name>
      <address>
        <city>Muenchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Schwaebisch-Gmuend</name>
      <address>
        <city>Mutlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Praxis Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studienzentrum Onkologie Ravensburg</name>
      <address>
        <city>Ravensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RoMed Klinikum Rosenheim</name>
      <address>
        <city>Rosenheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HELIOS Kliniken - HELIOS Klinik Rottweil</name>
      <address>
        <city>Rottweil</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HELIOS Kliniken - HELIOS Brustzentrums Nordachsen - HELIOS Klinik Schkeuditz</name>
      <address>
        <city>Schkeuditz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakonie-Klinikum Schwäbisch Hall gGmbH</name>
      <address>
        <city>Schwaebisch Hall</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leopoldina-Krankenhaus der Stadt Schweinfurt gGmbH</name>
      <address>
        <city>Schweinfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Landkreis Sigmaringen GmbH</name>
      <address>
        <city>Sigmaringen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Traunstein</name>
      <address>
        <city>Traunstein</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gesellschaft für onkologische Studien, Praxismanagement und -Logistik</name>
      <address>
        <city>Troisdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eberhard Karls Universitaet Tuebingen - Universitaetsfrauenklinik Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gesundheitszentren Rhein-Neckar - GRN-Klinik Weinheim</name>
      <address>
        <city>Weinheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis Wupperta</name>
      <address>
        <city>Wuppertal</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Trust - Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.eortc.be/clinicaltrials/details.asp?protocol=90091</url>
    <description>Related Info</description>
  </link>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 5, 2012</study_first_submitted>
  <study_first_submitted_qc>March 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2012</study_first_posted>
  <last_update_submitted>March 12, 2019</last_update_submitted>
  <last_update_submitted_qc>March 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Circulating Tumour Cells</keyword>
  <keyword>HER2 negative primary breast cancer</keyword>
  <keyword>HER2 positive CTC</keyword>
  <keyword>Trastuzumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

